Successful medical treatment of EBV smooth muscle tumor in a renal transplant recipient

Pediatric Transplantation

Volumn 14, Issue 8, 2010, Pages

  Belingheri, Mirco ^a   Comoli, Patrizia ^b   Locatelli, Franco ^b   Baldanti, Fausto ^b   Martina, Valentina ^a   Giani, Marisa ^a   Ferraresso, Mariano ^a   Cro, Lilla ^a   Edefonti, Alberto ^a   Ghio, Luciana ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

Author keywords

EBV; immunosuppression; kidney transplantation; smooth muscle tumor

Indexed keywords

CREATININE; CYCLOSPORIN A; METHYLPREDNISOLONE; PREDNISONE;

ACUTE GRAFT REJECTION; ADOLESCENT; ARTICLE; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CASE REPORT; CAUCASIAN; CONSERVATIVE TREATMENT; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; EPSTEIN BARR VIRUS INFECTION; GLOMERULONEPHRITIS; GRAFT RECIPIENT; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEIOMYOMA; MALE; NEEDLE BIOPSY; PERITONEAL DIALYSIS; VIRUS REACTIVATION;

ADOLESCENT; EPSTEIN-BARR VIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; KIDNEY NEOPLASMS; KIDNEY TRANSPLANTATION; MALE; SMOOTH MUSCLE TUMOR;

EID: 78649845953     PISSN: 13973142     EISSN: 13993046     Source Type: Journal    
DOI: 10.1111/j.1399-3046.2009.01213.x     Document Type: Article

References (18)

1. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: Current epidemiology and associated risk factors. Clin Transplant 2006: 4: 401-409.
2. Dharnidharka VR, Sullivan EK, Stablein DM, Tejani AH, Harmon WE, N orth A merican P ediatric R enal T ransplant C ooperative S tudy (NAPRTCS). Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: A report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 2001: 71: 1065-1068.
3. Andrés A,. Cancer incidence after immunosuppressive treatment following kidney transplantation. Crit Rev Oncol Hematol 2005: 56: 71-85.
4. Tao Q, Young LS, Woodman CB, Murray PG,. Epstein-Barr virus (EBV) and its associated human cancers-genetics, epigenetics, pathobiology and novel therapeutics. Front Biosci 2006: 11: 2672-2713.
5. Steiner M, Quinlan D, Goldman SM, et al. Leiomyoma of the kidney: Presentation of 4 new cases and the role of computerized tomography. J Urol 1990: 143: 994-998.
6. Sprangers B, Smets S, Sagaert X, et al. Posttransplant Epstein-Barr virus-associated myogenic tumors: Case report and review of the literature. Am J Transplant 2008: 8: 253-258.
7. Lee ES, Locker J, Nalesnik M, et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med 1995: 332: 19-25.
8. McClain KL, Leach CT, Jenson HB, et al. Association of Epstein-Barr virus with leiomyosarcomas in children with AIDS. N Engl J Med 1995: 332: 12-18.
9. Jenson HB, Leach CT, McClain KL, et al. Benign and malignant smooth muscle tumors containing Epstein-Barr virus in children with AIDS. Leuk Lymphoma 1997: 27: 303-314.
10. Deyrup AT, Lee VK, Hill CE, et al. Epstein-Barr virus-associated smooth muscle tumors are distinctive mesenchymal tumors reflecting multiple infection events: A clinicopathologic and molecular analysis of 29 tumors from 19 patients. Am J Surg Pathol 2006: 30: 75-82.
11. Frey NV, Tsai DE,. The management of posttransplant lymphoproliferative disorder. Med Oncol 2007: 24: 125-136.
12. Faller DV, Mentzer SJ, Perrine SP,. Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Curr Opin Oncol 2001: 13: 360-367.
13. Comoli P, Maccario R, Locatelli F, et al. Treatment of EBV-related post-renal transplant lymphoproliferative disease with a tailored regimen including EBV-specific T cells. Am J Transplant 2005: 5: 1415-1422.
14. Gottschalk S, Ng CY, Perez M, et al. An Epstein-Barr virus deletion mutant associated with fatal lymphoproliferative disease unresponsive to therapy with virus-specific CTLs. Blood 2001: 97: 835-843.
15. Hernando E, Charytonowicz E, Dudas ME, et al. The AKT-mTOR pathway plays a critical role in the development of leiomyosarcomas. Nat Med 2007: 13: 748-753.
16. Toh HC, Teo M, Ong KW, et al. Use of sirolimus for Epstein-Barr virus-positive smooth-muscle tumour. Lancet Oncol 2006: 7: 955-957.
17. Thong JF, Chuah KL,. EBV-associated smooth muscle tumour presenting as a parapharyngeal mass-a rare presentation. Auris Nasus Larynx 2009: 36: 120-122.
18. Tsai DE, Hardy CL, Tomaszewski JE, et al. Reduction in immunosuppression as initial therapy for posttransplant lymphoproliferative disorder: Analysis of prognostic variables and long-term follow-up of 42 adult patients. Transplantation 2001: 71: 1076-1088.